Treatment of multiresistant prolactinomas with a combination of cabergoline and octreotide LAR.

The addition of a somatostatin analog to ongoing CBG treatment may be effective in some patients with DA-resistant macroprolactinomas, independently of the adenoma's SSTR expression profile.